Quoin Pharmaceuticals reports positive interim Phase 2/3 data for QRX003
Quoin Pharmaceuticals reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton syndrome.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.